Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FMN1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FMN1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FMN1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FMN1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FMN1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00720091 | Colorectum | CRC | nephron epithelium development | 24/2078 | 109/18723 | 7.49e-04 | 9.60e-03 | 24 |
GO:00720061 | Colorectum | CRC | nephron development | 29/2078 | 142/18723 | 8.29e-04 | 1.04e-02 | 29 |
GO:00613261 | Colorectum | CRC | renal tubule development | 21/2078 | 94/18723 | 1.28e-03 | 1.44e-02 | 21 |
GO:00720801 | Colorectum | CRC | nephron tubule development | 20/2078 | 91/18723 | 2.04e-03 | 2.03e-02 | 20 |
GO:19018883 | Colorectum | CRC | regulation of cell junction assembly | 36/2078 | 204/18723 | 3.30e-03 | 2.84e-02 | 36 |
GO:0048705 | Colorectum | CRC | skeletal system morphogenesis | 37/2078 | 220/18723 | 6.58e-03 | 4.71e-02 | 37 |
GO:001081015 | Endometrium | AEH | regulation of cell-substrate adhesion | 64/2100 | 221/18723 | 3.85e-13 | 9.62e-11 | 64 |
GO:00315899 | Endometrium | AEH | cell-substrate adhesion | 87/2100 | 363/18723 | 3.51e-12 | 5.70e-10 | 87 |
GO:000701516 | Endometrium | AEH | actin filament organization | 98/2100 | 442/18723 | 1.99e-11 | 2.98e-09 | 98 |
GO:004578516 | Endometrium | AEH | positive regulation of cell adhesion | 96/2100 | 437/18723 | 5.50e-11 | 7.18e-09 | 96 |
GO:003297016 | Endometrium | AEH | regulation of actin filament-based process | 89/2100 | 397/18723 | 9.14e-11 | 1.10e-08 | 89 |
GO:190290316 | Endometrium | AEH | regulation of supramolecular fiber organization | 83/2100 | 383/18723 | 2.20e-09 | 1.78e-07 | 83 |
GO:001081116 | Endometrium | AEH | positive regulation of cell-substrate adhesion | 38/2100 | 123/18723 | 3.08e-09 | 2.26e-07 | 38 |
GO:003295616 | Endometrium | AEH | regulation of actin cytoskeleton organization | 77/2100 | 358/18723 | 1.18e-08 | 7.76e-07 | 77 |
GO:00019529 | Endometrium | AEH | regulation of cell-matrix adhesion | 37/2100 | 128/18723 | 3.58e-08 | 1.99e-06 | 37 |
GO:015011610 | Endometrium | AEH | regulation of cell-substrate junction organization | 25/2100 | 71/18723 | 8.77e-08 | 4.42e-06 | 25 |
GO:015011510 | Endometrium | AEH | cell-substrate junction organization | 31/2100 | 101/18723 | 1.01e-07 | 4.99e-06 | 31 |
GO:003253510 | Endometrium | AEH | regulation of cellular component size | 78/2100 | 383/18723 | 1.10e-07 | 5.29e-06 | 78 |
GO:00480418 | Endometrium | AEH | focal adhesion assembly | 28/2100 | 87/18723 | 1.36e-07 | 6.14e-06 | 28 |
GO:00071609 | Endometrium | AEH | cell-matrix adhesion | 54/2100 | 233/18723 | 1.42e-07 | 6.37e-06 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FMN1 | SNV | Missense_Mutation | | c.2578A>G | p.Met860Val | p.M860V | Q68DA7 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
FMN1 | SNV | Missense_Mutation | rs200873951 | c.3700C>T | p.Arg1234Cys | p.R1234C | Q68DA7 | protein_coding | deleterious(0) | possibly_damaging(0.685) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FMN1 | SNV | Missense_Mutation | | c.3587G>A | p.Arg1196Lys | p.R1196K | Q68DA7 | protein_coding | tolerated(0.09) | possibly_damaging(0.809) | TCGA-AO-A12A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
FMN1 | SNV | Missense_Mutation | novel | c.4081G>A | p.Asp1361Asn | p.D1361N | Q68DA7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
FMN1 | SNV | Missense_Mutation | | c.2522N>A | p.Leu841His | p.L841H | Q68DA7 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.781) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
FMN1 | SNV | Missense_Mutation | | c.2233G>C | p.Glu745Gln | p.E745Q | Q68DA7 | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
FMN1 | SNV | Missense_Mutation | | c.3868N>C | p.Glu1290Gln | p.E1290Q | Q68DA7 | protein_coding | tolerated(0.2) | possibly_damaging(0.466) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FMN1 | SNV | Missense_Mutation | novel | c.1679N>C | p.Arg560Pro | p.R560P | Q68DA7 | protein_coding | tolerated_low_confidence(0.06) | benign(0.076) | TCGA-OL-A5RV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
FMN1 | deletion | Frame_Shift_Del | novel | c.2111delN | p.Pro704GlnfsTer12 | p.P704Qfs*12 | Q68DA7 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
FMN1 | deletion | Frame_Shift_Del | | c.3041delN | p.Asp1014AlafsTer49 | p.D1014Afs*49 | Q68DA7 | protein_coding | | | TCGA-E2-A156-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |